FDA-approved1,2Evidence: Large human trialsHormones · Sexual and reproductive health · Cancer

Goserelin1

Also called Zoladex1,2

Key takeaway

Goserelin is a lab-made decapeptide analogue of gonadotropin-releasing hormone (GnRH) and the active ingredient in Zoladex.1,2 FDA first approved Zoladex in 1989. The cited label covers prostate cancer, endometriosis, thinning the uterine lining before endometrial ablation, and advanced breast cancer in pre- and perimenopausal women.1,2 Its label describes randomized trials, including one of 466 men in which adding Zoladex and flutamide to radiation lowered local prostate cancer failure at four years.1

Goserelin at a glance

What it isA synthetic decapeptide analogue of GnRH that, with continued use, suppresses the pituitary’s release of reproductive hormones, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Zoladex with an original approval date of December 29, 1989. The cited label has no boxed warning.1,2
Human evidenceRandomized and controlled trials in prostate cancer, endometriosis, abnormal uterine bleeding and breast cancer, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is goserelin?

Goserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH), the hypothalamic peptide that controls the pituitary’s reproductive hormones.1

In the United States it is the active ingredient of Zoladex, from TerSera Therapeutics, according to Drugs@FDA.2

How does goserelin work?

The label states that goserelin acts as an inhibitor of pituitary gonadotropin secretion when given in its long-acting form, lowering testosterone in men and estrogen in women.1

In animal and laboratory studies, goserelin caused hormone-sensitive breast and prostate tumors to shrink or stop growing, according to the label. The label also notes that tumor symptoms can briefly worsen in the first weeks.1

What do human studies show?

In a controlled trial of 466 men with bulky prostate cancer, adding Zoladex and flutamide to radiation lowered the four-year rate of local failure from 33% to 16% and lengthened median disease-free survival from 2.6 to 4.4 years, according to the label.1

In two endometriosis trials, Zoladex was as effective as danazol at relieving symptoms, and 63% and 62% of women on Zoladex had at least a 50% reduction in lesions, according to the label.1

In a randomized trial of 358 women before endometrial ablation, 40% of those given Zoladex reported no menstrual periods six months after surgery, compared with 26% given placebo, according to the label.1

In premenopausal women with hormone-receptor-positive advanced breast cancer, interim data on 124 women in a randomized trial showed a 22% objective response with Zoladex versus 12% with removal of the ovaries, according to the label.1

What the evidence base contains

  • Controlled human trial A multicenter, controlled trial in 466 men with prostate cancer confined to the pelvis comparing Zoladex plus flutamide and radiation with radiation alone, described in the label as a basis of its prostate cancer indication.1
  • Large randomized human trial Trial 0022: a double-blind, randomized, placebo-controlled trial in 358 participants, premenopausal women with abnormal uterine bleeding before endometrial ablation, described in the label as a basis of that indication.1
  • Controlled human trial Controlled trials comparing Zoladex with danazol in endometriosis and a randomized trial comparing it with removal of the ovaries in breast cancer, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is goserelin FDA-approved?

Yes. Drugs@FDA lists Zoladex, application NDA 019726, with an original approval date of December 29, 1989.2

The Zoladex label cited here (DailyMed SPL version 9, published March 26, 2026) states that it is indicated for prostate cancer with flutamide and radiation, palliative treatment of advanced prostate cancer, endometriosis, endometrial thinning before ablation, and palliative treatment of advanced breast cancer in pre- and perimenopausal women.1

The label has no boxed warning. It states that Zoladex is contraindicated in pregnancy unless used for advanced breast cancer, and its warnings include tumor flare, high blood sugar, heart attack and stroke risk reported in men, and severe skin reactions.1

Timeline

  1. FDA approves Zoladex, according to Drugs@FDA.2
  2. DailyMed publishes the Zoladex label version cited on this page.1

What is still unknown?

The label states that there is insufficient evidence to determine whether pregnancy rates are improved or harmed by its use.1

Results of the breast cancer comparison beyond its interim analysis: the label reports interim data from 124 women.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Goserelin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Goserelin are a bounded selection, not every registration or paper about Goserelin. For the years before Goserelin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Goserelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Goserelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis. The label describes randomized and controlled trials in each approved use, including a 466-man prostate cancer trial and a 358-woman placebo-controlled trial before endometrial ablation.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Goserelin?

FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis. The label describes randomized and controlled trials in each approved use, including a 466-man prostate cancer trial and a 358-woman placebo-controlled trial before endometrial ablation.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
17
Drugs@FDA applications
2

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 12, 2026

ClinicalTrials.gov record NCT07310420↗Added to PeptideScanner November 15, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Goserelin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

64Selected dated records
66Connected citations
17Populated source years1989–2026
3/4Record lanes present

Registered human studies

Trial composition

30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 2 14Phase 3 10Phase 1 3Phase 4 2Not applicable 1
Status at observationCompleted 26Active, not recruiting 3Recruiting 1

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Randomized Controlled Trial 13Clinical Trial 12Research Support, Non-U.S. Gov't 11Multicenter Study 10Comparative Study 6Review 6Clinical Trial, Phase II 5English Abstract 4Clinical Trial, Phase III 3Research Support, U.S. Gov't, P.H.S. 2Case Reports 1Clinical Trial, Phase IV 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
2
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
64

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 64 dated records

Research hub

Explore the Goserelin evidence record

Open all 64 records →
64Dated records
3Evidence types
64Cited public sources
17Source years

Change ledger

Recently changed for Goserelin

Open all 64 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00004124

PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
December 30, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00005044

PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
June 15, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00108732

PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.

PeptideScanner change date
November 15, 2026
Cited source date
June 30, 2015
Evidence lane
Clinical trials

Official-source collections

Source records for Goserelin

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Roles of Goserelin in Gynecological Disorders.Drug design, development and therapy · 2026 05 27
  2. [Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].Zhonghua zhong liu za zhi [Chinese journal of oncology] · 2025 Apr 23
  3. Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASU.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024 Aug 15
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07310420Registry update November 12, 2026 · current at observation
  2. NCT02115282Registry update October 22, 2026 · current at observation
  3. NCT05161195Registry update October 19, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span December 29, 1989 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 64

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07310420↗

    PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02115282↗

    PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT05161195↗

    PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT02003209↗

    PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT01723774↗

    PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin.↗

  6. Literature metadata

    Roles of Goserelin in Gynecological Disorders.↗

    PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT03671330↗

    PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin.↗

  8. Literature metadata

    Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.↗

    PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Goserelin ('Zoladex')--offering patients more choice in early breast cancer.↗

    PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    A Phase II trial of Zoladex combined with CEF chemotherapy as neoadjuvant therapy in premenopausal women with hormone-responsive, operable breast cancer.↗

    PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Literature metadata

    Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.↗

    PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Literature metadata

    Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.↗

    PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026